In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on PDS Biotechnology (PDSB – Research Report), with a price target of $15.00. The company’s shares opened today at $3.46.
Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and PDS Biotechnology. According to TipRanks, Pantginis has an average return of -23.4% and a 22.16% success rate on recommended stocks.
Currently, the analyst consensus on PDS Biotechnology is a Strong Buy with an average price target of $18.50.
See the top stocks recommended by analysts >>
PDSB market cap is currently $97.9M and has a P/E ratio of -3.46.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
Read More on PDSB:
- PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
- PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
- PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update
- PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
